» Articles » PMID: 27862942

A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4 or CD8 T Cells Using Immunodeficient NOG Mice

Overview
Journal Am J Transplant
Publisher Elsevier
Specialty General Surgery
Date 2016 Nov 19
PMID 27862942
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Graft-versus-host disease (GVHD) is a major complication of allogenic bone marrow transplantation and involves the infiltration of donor CD4 and/or CD8 T cells into various organs of the recipient. The pathological role of human CD4 and CD8 T cells in GVHD remains controversial. In this study, we established two novel xenogeneic (xeno)-GVHD models. Human CD4 or CD8 T cells were purified from peripheral blood and were transplanted into immunodeficient NOD/Shi-scid IL2rg (NOG) mice. Human CD8 T cells did not induce major GVHD symptoms in conventional NOG mice. However, CD8 T cells immediately proliferated and induced severe GVHD when transferred into NOG mice together with at least 0.5 × 10 CD4 T cells or into NOG human interleukin (IL)-2 transgenic mice. Human CD4 T cell-transplanted NOG mice developed skin inflammations including alopecia, epidermal hyperplasia, and neutrophilia. Pathogenic T helper (Th)17 cells accumulated in the skin of CD4 T cell-transplanted NOG mice. Further, an anti-human IL-17 antibody (secukinumab) significantly suppressed these skin pathologies. These results indicate that pathogenic human Th17 cells induce cutaneous GVHD via IL-17-dependent pathways. This study provides fundamental insights into the pathogenesis of xeno-GVHD, and these humanized mouse models may be useful as preclinical tools for the prevention of GVHD.

Citing Articles

Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice.

Ehx G, Ritacco C, Baron F Biomark Res. 2024; 12(1):139.

PMID: 39543777 PMC: 11566168. DOI: 10.1186/s40364-024-00684-9.


Multimodal analysis identifies microbiome changes linked to stem cell transplantation-associated diseases.

Artacho A, Gonzalez-Torres C, Gomez-Cebrian N, Moles-Poveda P, Pons J, Jimenez N Microbiome. 2024; 12(1):229.

PMID: 39511587 PMC: 11542268. DOI: 10.1186/s40168-024-01948-0.


MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers.

Eguren-Santamaria I, Fernandez de Pierola E, Camps G, Martin-Munoz P, Campos M, Cuculescu D J Immunother Cancer. 2024; 12(9).

PMID: 39244214 PMC: 11381650. DOI: 10.1136/jitc-2023-008516.


Disruption of IFNγ, GZMB, PRF1, or LYST Results in Reduced Suppressive Function in Human CD8+ T Cells.

Vemulawada C, Renavikar P, Crawford M, Steward-Tharp S, Karandikar N J Immunol. 2024; 212(11):1722-1732.

PMID: 38607279 PMC: 11105984. DOI: 10.4049/jimmunol.2300388.


Human MAIT cells inhibit alloreactive T cell responses and protect against acute graft-versus-host disease.

Talvard-Balland N, Lambert M, Chevalier M, Minet N, Salou M, Tourret M JCI Insight. 2024; 9(5).

PMID: 38300704 PMC: 11143928. DOI: 10.1172/jci.insight.166310.